Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078165 | 1.00 | EPHX1 (0.45) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL8744318 | 1.00 | EPHX1 (0.45) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL8744392 | 1.00 | EPHX1 (0.45) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL2167450 | 1.00 | EPHX1 (0.45) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL8744391 | 1.00 | EPHX1 (0.45) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL8544644 | 1.00 | EPHX1 (0.45) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL127722 | 0.98 | EPHX1 (0.42) | EPHX1EP300TSHRTERTPTPN1 | |
| SCHEMBL127597 | 0.91 | — | — | |
| SCHEMBL128030 | 0.81 | — | — | |
| SCHEMBL23924683 | 0.81 | FAAH (0.51) | EP300TSHRTERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| EP-2243805-B1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2014-11-26 | — | — | EP | disclosed |
| EP-2341108-B1 | Surface treatment method for solid material | SHINETSU CHEMICAL CO (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8541631-B2 | Surface treatment method for solid material | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-7985287-B2 | Anthrapyridone compound or a salt thereof, magenta ink composition containing the anthrapyridone compound and colored product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| EP-2341108-A1 | Surface treatment method for solid material | Shin-Etsu Chemical Co., Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20110160464-A1 | SURFACE TREATMENT METHOD FOR SOLID MATERIAL | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2243805-A1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | Nippon Kayaku Kabushiki Kaisha (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-7322927-B2 | Hybrid phthalocyanine derivatives and their uses | BIOSITE, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-6251687-B1 | PARTICLE CONTAINING ENERGY DONOR AND ENERGY ACCEPTOR | BIOSITE DIAGNOSTICS, INC. | 2001-06-26 | — | — | US | disclosed |
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5462965-A | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | GD SEARLE & CO. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | disclosed |
| US-4758637-A | Silicone-modified polyester resin and silicone-sheathed polyester fibers made therefrom | UNION CARBIDE CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0269023-A2 | Silicone-modified polyester resin and silicone-sheathed polyester fibers made therefrom | UNION CARBIDE CORPORATION (US) | 1988-06-01 | — | — | EP | disclosed |
| US-4510159-A | (+)-Cyanidan-3-ol derivatives, pharmaceutical preparations that contain such compounds, and the use of the latter to treat liver or venous diseases | ZYMA SA (CH) | 1985-04-09 | — | — | US | disclosed |
| EP-0096008-A2 | (+)-Cyanidan-3-ol derivatives, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter | Zyma SA (CH) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160464-A1 | SURFACE TREATMENT METHOD FOR SOLID MATERIAL | H1-2, H1-0, HRH3 | EPHX1 4140/4885EP300 482/4885TSHR 814/4885 |
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | MLLT3, MLLT1, H1-3 | EPHX1 3796/4885EP300 438/4885TSHR 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.